 David Wofsy, MD
|
| Title | Professor in Residence |
|---|
| School | UCSF School of Medicine |
|---|
| Department | Medicine |
|---|
| Address | VAMC Bldg 2
|
|---|
| Phone | 415-750-2104 |
|---|
|
|
 Biography | American College of Rheumatology | 2012 | | Master of the American College of Rheumatology | | New York Academy of Medicine | 2011 | | Paul Klemperer Award and Medal | | Arthritis Foundation | 2007 | | Lee C. Howley Sr. Prize | | Arthritis Foundation | 2001 | | Arthritis Hero Award | | American College of Rheumatology | 1999 | | Edmund L. Dubois Award for Outstanding Research in SLE |
Overview Dr. Wofsy received his undergraduate degree from Harvard (1968), his MD from the University of California, San Diego (1974), and his medical residency training and rheumatology fellowship training from the University of California, San Francisco. He joined the UCSF faculty in 1980. He currently Professor of Medicine and Microbiology/Immunology at UCSF. Dr. Wofsy also serves as Associate Dean for Admissions for the UCSF School of Medicine. He has served on numerous NIH study sections, and on the Arthritis Advisory Committee of the Food and Drug Administration. Dr. Wofsy is a past-President of the American College of Rheumatology.
Dr. Wofsy's research program is devoted to the development of novel therapies for autoimmune diseases, particularly systemic lupus erythematosus (SLE). For many years, his research focused on the cellular and molecular mechanisms that lead to autoimmunity in murine models for SLE. These therapies are designed to block pathologic immune responses without damaging the entire immune system. One of the therapies that was pioneered by Dr. Wofsy's group involves the B7 family of molecules on antigen-presenting cells (APC). These molecules play a pivotal role in the generation of T-cell help. Specifically, the interaction of B7 molecules on APC with their ligand (designated CD28) on T cells provides an important signal for T-cell activation. Dr. Wofsy first showed that selective inhibition of the B7-CD28 interaction retards autoimmunity in murine lupus. He subsequently showed that this beneficial effect could be enhanced substantially in two ways: (i) by combining blockade of B7-CD28 with blockade of other receptor-ligand pairs (CD40-CD40L) on the surface of T cells and APC; and (ii) by combining blockade of B7-CD28 with cyclophosphamide therapy. In each case, combination therapy provided a prolonged benefit without sustained generalized immune suppression. This work laid the foundation for translational studies that resulted in FDA approval of a new treatment for rheumatoid arthritis. Dr.Wofsy's current research is focused on establishing whether this therapy can be life-saving in people with kidney disease due to SLE.
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Researchers can login to make corrections and additions, or contact us for help.
-
Wofsy D. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. Ann Rheum Dis. 2013 Apr; 72 Suppl 2:ii66-ii68.
-
Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 Nov; 64(11):3660-5.
-
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17; 365(20):1886-95.
-
Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):846-54.
-
Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7.
-
Papadakis MA, Wofsy D. Plagiarism on personal statements: a disturbing symptom of a broader trend. Ann Intern Med. 2010 Jul 20; 153(2):128-9.
-
Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5.
-
Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 Jan; 62(1):211-21.
-
Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3.
-
Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010 Jan; 49(1):128-40.
-
Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5.
-
Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51.
-
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May; 20(5):1103-12.
-
Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009 Apr 1; 301(13):1367-72.
-
Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, Yelin E. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum. 2009 Mar 15; 61(3):370-7.
-
Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50.
-
Sinclair A, Appel G, Dooley MA, Ginzler E, Isenberg D, Jayne D, Wofsy D, Solomons N. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007; 16(12):972-80.
-
Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80.
-
Daikh DI, Gillis J, Wofsy D. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Arthritis Rheum. 2006 Apr 15; 55(2):322-4.
-
Wofsy D. Living in a different world. Arthritis Rheum. 2005 Feb; 52(2):395-401.
-
Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus. 2005; 14(3):197-203.
-
Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
-
Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum. 2001 Aug; 44(8):1730-5.
-
Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 Mar 1; 166(5):2913-6.
-
Wada T, Schwarting A, Chesnutt MS, Wofsy D, Rubin Kelley V. Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets. Kidney Int. 2001 Feb; 59(2):565-78.
-
Daikh DI, Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol. 2001; 490:113-7.
-
Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan; 28(1):95-101.
-
Jeddi P, Keusch J, Lydyard PM, Bodman-Smith KB, Chesnutt MS, Wofsy D, Hirota H, Taga T, Delves PJ. The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G. Immunology. 1999 Nov; 98(3):475-80.
-
Daikh DI, Wofsy D. Effects of anti-B7 monoclonal antibodies on humoral immune responses. J Autoimmun. 1999 Mar; 12(2):101-8.
-
Daikh DI, Wofsy D. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Transplant Proc. 1998 Dec; 30(8):4027-8.
-
Wofsy D, Daikh DI. Opportunities for future biological therapy in SLE. Baillieres Clin Rheumatol. 1998 Aug; 12(3):529-41.
-
Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice. Clin Immunol Immunopathol. 1998 Apr; 87(1):23-32.
-
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 1; 159(7):3104-8.
-
Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol. 1997 Aug; 62(2):156-62.
-
Adleman LM, Wofsy D. Blind T-cell homeostasis in CD4-deficient mice. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 1; 11(4):334-40.
-
Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994 Aug 26; 265(5176):1225-7.
-
Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994 Aug; 94(2):585-91.
-
Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol. 1994 Aug; 72(2):198-203.
-
Wofsy D. Recent advances in the treatment of rheumatic diseases: new approaches to immunotherapy. Ryumachi. 1994 Apr; 34(2):164-5.
-
Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection . J Acquir Immune Defic Syndr. 1993 Feb; 6(2):144-52.
-
Wofsy D. Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunol Ser. 1993; 59:221-36.
-
Finck BK, Yung CM, Carteron NL, Wofsy D. The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies. Clin Immunol Immunopathol. 1992 Dec; 65(3):234-41.
-
Connolly K, Roubinian JR, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol. 1992 Nov 1; 149(9):3083-8.
-
Jäck HM, Beck-Engeser G, Lee G, Wofsy D, Wabl M. Tumorigenesis mediated by an antigen receptor. Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8482-6.
-
Wofsy D, Carteron NL. CD4 antibody therapy in systemic lupus erythematosus. Semin Immunol. 1990 Nov; 2(6):419-25.
-
Wofsy D. Regulation of immunity by anti-T-cell antibodies. West J Med. 1990 Sep; 153(3):265-8.
-
Carteron NL, Wofsy D, Schimenti C, Ermak TH. F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T cells, CD8+ T cells, and B cells in the kidneys of lupus-prone NZB/NZW mice. Clin Immunol Immunopathol. 1990 Sep; 56(3):373-83.
-
Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol. 1990 Mar 1; 144(5):1753-8.
-
Ermak TH, Steger HJ, Wofsy D. Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node. Lab Invest. 1989 Oct; 61(4):447-56.
-
Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989 Sep; 52(3):421-34.
-
Erlich KS, Wofsy D, Dix RD, Mills J. Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis. Clin Immunol Immunopathol. 1989 Aug; 52(2):190-201.
-
Carteron NL, Schimenti CL, Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 1; 142(5):1470-5.
-
Klippel JH, Strober S, Wofsy D. New therapies for the rheumatic diseases. Bull Rheum Dis. 1989; 38(4):1-8.
-
Wofsy D, Chiang NY, Greenspan JS, Ermak TH. Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune disease. J Autoimmun. 1988 Oct; 1(5):415-31.
-
Wofsy D. The role of Lyt-2+ T cells in the regulation of autoimmunity in murine lupus. J Autoimmun. 1988 Apr; 1(2):207-17.
-
Carteron NL, Wofsy D, Seaman WE. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol. 1988 Feb 1; 140(3):713-6.
-
Wofsy D. Treatment of autoimmune diseases with monoclonal antibodies. Prog Allergy. 1988; 45:106-20.
-
Seaman WE, Wofsy D. Selective manipulation of the immune response in vivo by monoclonal antibodies. Annu Rev Med. 1988; 39:231-41.
-
Wofsy D. New approaches to treating systemic lupus erythematosus. West J Med. 1987 Aug; 147(2):181-6.
-
Wofsy D, Chiang NY. Proliferation of Ly-1 B cells in autoimmune NZB and (NZB x NZW)F1 mice. Eur J Immunol. 1987 Jun; 17(6):809-14.
-
Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987 May 15; 138(10):3247-53.
-
Gutstein NL, Wofsy D. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol. 1986 Dec 1; 137(11):3414-9.
-
Woodcock J, Wofsy D, Eriksson E, Scott JH, Seaman WE. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation. 1986 Dec; 42(6):636-42.
-
Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15; 137(4):1127-32.
-
Wofsy D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol. 1986 Jun 15; 136(12):4554-60.
-
Stanton T, Stevens TL, Ledbetter JA, Wofsy D. Anti-Ly-1 antibody induces interleukin 2 release from T cells. J Immunol. 1986 Mar 1; 136(5):1734-7.
-
Wofsy D, Seaman WE. Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4. Immunol Res. 1986; 5(2):97-105.
-
Wofsy D. Strategies for treating autoimmune disease with monoclonal antibodies. West J Med. 1985 Dec; 143(6):804-9.
-
Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol. 1985 Oct; 135(4):2331-6.
-
Wofsy D, Mayes DC, Woodcock J, Seaman WE. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol. 1985 Sep; 135(3):1698-701.
-
Wofsy D, Ledbetter JA, Hendler PL, Seaman WE. Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985 Feb; 134(2):852-7.
-
Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1; 161(2):378-91.
-
Wofsy D, Hardy RR, Seaman WE. The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens. J Immunol. 1984 Jun; 132(6):2686-9.
-
Wofsy D, Kerger CE, Seaman WE. Monocytosis in the BXSB model for systemic lupus erythematosus. J Exp Med. 1984 Feb 1; 159(2):629-34.
-
Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr; 130(4):1713-8.
-
Shear HL, Wofsy D, Talal N. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. Clin Immunol Immunopathol. 1983 Mar; 26(3):361-9.
-
Talal N, Dauphinee MJ, Wofsy D. Interleukin-2 deficiency, genes, and systemic lupus erythematosus. Arthritis Rheum. 1982 Jul; 25(7):838-42.
-
Wofsy D, Ledbetter JA, Roubinian JR, Seaman WE, Talal N. Thymic influences on autoimmunity in MRL-lpr mice. Scand J Immunol. 1982 Jul; 16(1):51-8.
-
Dauphinée MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol. 1981 Dec; 127(6):2483-7.
-
Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med. 1981 Nov 1; 154(5):1671-80.
-
Wofsy D, Dauphinée MJ, Kipper SB, Talal N. Interleukin-2 deficiency in murine systemic lupus erythematosus. Trans Assoc Am Physicians. 1981; 94:341-8.
-
Wofsy D. Culture-negative septic arthritis and bacterial endocarditis. Diagnosis by synovial biopsy. Arthritis Rheum. 1980 May; 23(5):605-7.
-
Loeb JM, Livermore BM, Wofsy D. Coccidioidomycosis of the thyroid. Ann Intern Med. 1979 Sep; 91(3):409-11.
|
David's Networks
Click the "See All" links for more information and interactive visualizations!
Related Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Related Authors People who share similar concepts with this person. _
|
